Status:
COMPLETED
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
Lead Sponsor:
Pfizer
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse event...
Eligibility Criteria
Inclusion
- Patients with open angle glaucoma and/or ocular hypertension requiring a reduction of IOP who were insufficiently responsive to topical betablockers
Exclusion
- Previous and current treatment with any topical ophthalmic drug containing prostaglandins; any condition in which treatment with the betablocking agent, timolol, was contraindicated.
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
976 Patients enrolled
Trial Details
Trial ID
NCT00150267
Start Date
February 1 2002
Last Update
November 5 2008
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Sydney, New South Wales, Australia, 2000
2
Pfizer Investigational Site
Sydney, New South Wales, Australia, 2067
3
Pfizer Investigational Site
Antwerp, Belgium, 2020
4
Pfizer Investigational Site
Brussels, Belgium, 1090